AI brief of an SEC Form 8-K · LeMaitre Vascular (LMAT)

LeMaitre Vascular director Jasinski lost shareholder vote; board rejected his resignation

Neutral Impact 3 of 5 shareholder Written later

At its June 3, 2024 annual meeting, LeMaitre Vascular shareholders re-elected or elected three Class III directors, but Lawrence J. Jasinski received 8,277,096 votes for and 11,308,332 withheld. Under the company's governance guidelines he tendered his resignation, but the board rejected it after considering the Nominating and Corporate Governance Committee's recommendation. Shareholders also approved an amended stock option and incentive plan that authorizes 1,000,000 new shares and extends the plan to June 3, 2034.

Key points

  • Jasinski received fewer votes for than against his election; the board rejected his resignation on June 3, 2024
  • Amended and restated stock option plan approved with 19,332,353 votes for and 411,532 against, adding 1,000,000 shares and running to June 3, 2034
  • Advisory say-on-pay vote approved with 19,118,371 votes for and 624,991 against
  • Grant Thornton LLP ratified as independent auditor for the year ending December 31, 2024 (20,642,552 for, 93,844 against)

The filing

CompanyLeMaitre Vascular (LMAT)
Form8-K, current report
Filed with the SECJun 3, 2024, 4:21 PM ET
Accession number0001437749-24-019032

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 03, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.